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The role of high-risk human papillomavirus (hrHPV) testing in primary cervical screening has not been established. We generated a
randomised evaluation design ultimately to clarify whether primary hrHPV testing implemented into routine screening can bring
increase in the programme effectiveness. The aim of the present report on first-year results was to assess the cross-sectional relative
validity parameters for routine hrHPV screening, in comparison with conventional screening. An equal number of women invited to
routine screening was randomly allocated to primary hrHPV screening (n¼7060) and to cytological screening (n¼7089). In the
hrHPV screening arm, after a single positive hrHPV test result, the need of colposcopy referral was determined by a cytological triage
test. Compared with the conventional arm, more colposcopy referrals were made in the hrHPV screening arm (relative risk 1.51,
confidence interval 95% 1.03–2.22). Specificity of the primary screening with sole hrHPV test (91.5–92.1%) was much lower than
that with the cytology triage (98.7–99.3%), which was not quite as specific as screening with conventional cytology (99.2–99.6%).
Compared with conventional cytology, primary screening with hrHPV test results in increased cross-sectional relative sensitivity at the
level of all positive lesions at the cost of substantial loss in specificity. With cytology triage, the specificity improves to the level of
conventional cytology.
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On the area of cervical cancer prevention, much emphasis and
hope has lately been given on human papillomavirus (HPV)
vaccines being tested around the world (Koutsky et al, 2002;
Harper et al, 2004; Munoz et al, 2004). Nevertheless, organised
population-based screening is still the most effective way to
control for cervical cancer (The working group of IARC, 2005).
First screening programmes were based on a conventional
Papanicolaou or ‘Pap’ smear analysed with light microscopy.
However, with evolution of medical technology, alternative
screening modalities have been developed and introduced into
the routine screening in increasing numbers (Noorani et al, 2003;
Anttila et al, 2004; Nieminen et al, 2005; The working group of
IARC, 2005). Establishing the key role of certain human
papillomavirus types (referred as high-risk HPVs (hrHPVs)) in
causing cervical cancer has given birth to the generation of
aetiology-based screening tests (Schiffman et al, 1993; Bosch et al,
1995; Jacobs et al, 1997; Walboomers et al, 1999; Lorincz, 2003).
Recently, the role of high-risk HPV testing in primary screening
has been a subject of wide interest. Screening for hrHPVs is
suggested to be beneficial, especially in settings where it is used to
clarify the importance of cytological test result (Castle et al, 2002;
Lorincz and Richart, 2003; Noorani et al, 2003; Arbyn et al, 2004;
Wright et al, 2004; The working group of IARC, 2005). Instead,
whether primary hrHPV testing implemented into an existing and
well-functioning public-health screening programme can bring
increase in the programme effectiveness is not known. To study
this, the commercial hrHPV detection test, HC 2
r, has been
implemented by randomisation into the Finnish cervical cancer
screening programme as the primary screening test since 2003.
The aim of the current report on first-year results is to assess the
relative validity parameters, that is, cross-sectional sensitivity and
specificity, for routine hrHPV screening, in comparison with
conventional screening.
MATERIALS AND METHODS
Finnish cervical screening programme
Finnish cervical screening programme is organised and nation-wide,
targeted for 30–60-year-old women. Individual municipalities are
responsible for the costs and practical arrangements. The screening
interval is 5 years, unless intensified (or risk group) screening is
indicated by previous screening test result or reported symptoms; in
this case, the screening interval is shortened to 1 year (Hakama et al,
1979; Anttila & Nieminen, 2000). Women belonging to the target
population are identified from the national Population Registry and
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sinvited by a personal letter to free cervical screening. During the
screening visit a trained nurse or midwife takes the screening
sample, traditionally a cytological smear of three cervicovaginal
subsamples (vaginal, cervical and endocervical), that is, a VCE
smear. In addition to this, for each participant the sample-taker fills
an information form of recent gynaecological history. Completed
forms and fixed samples are sent to screening laboratories for
further processing and analysis. Eventually, screening results are
mailed from the screening laboratories to the attended women.
However, if colposcopy is indicated on the basis of the screening
result, the woman is generally contacted first by phone.
Primary smear analysis is performed in screening laboratories
by cytotechnicians. A pathologist re-screens all the slides with any
abnormalities and a small fraction of the slides classified normal.
The cytology results are reported according to modified Papani-
colaou classification, in which the specimen adequacy is evaluated
and descriptive diagnosis given in addition to designating the
cytological findings class I (normal) through to class V (malig-
nant). Women with class III–V smears (mild, moderate and severe
dyskaryosis as well as carcinoma cells in British terminology; ASC-
H, LSIL, HSIL and glandular atypia in TBS 2001) are directly
referred for colposcopy. Instead, class II smears (borderline
changes in British terminology, reactive and ASC-US in TBS
2001) are considered essentially benign in cellular changes and,
thus, they are most often recommended to control for by a new
smear after 6–12 months or after the possible medicinal treatment.
In addition, in most municipalities women with class II smears are
invited to intensified screening after 1 year. Screening-induced
colposcopies and other possible confirmatory tests are conducted
mainly in regional hospitals, where the possible histologically
confirmed precancerous lesions are treated and their postopera-
tional follow-up is carried out. Women with negative histological
confirmation are invited to intensified screening a year after.
For each screening episode within the invitational programme,
the data on screening test results, colposcopy referrals and
histological findings are sent by the screening laboratory personnel
to the Mass Screening Registry of the Finnish Cancer Registry.
Mass Screening Registry does not collect any information on
smears from outside the organised programme.
Study design
The routine screening target population of seven committed
municipalities (Hyvinka ¨a ¨,J a ¨rvenpa ¨a ¨, Kirkkonummi, Lohja, Porvoo,
Tuusula, Vantaa) was individually randomised 1:1 to the hrHPV
screening arm with primary hrHPV screening (HC 2
r by Digene
Corporation, MD, USA) with cytology triage and to the control arm
with conventional cytological testing by randomly allocating the
women on the basis of their personal identifiers, while drawing the
invitational information from the Population Registry files. Each
identified woman was invited with a similar personal letter mailed
together with a special information brochure. Individual randomi-
sation status was not revealed in the letter, but it was registered to
the Mass Screening Registry, from where it was controlled, that the
randomised women would get the same statuses each time they
were invited within the programme.
In the control arm, screening visit procedures were not altered
from the previous routine. Instead, in the hrHPV arm two separate
samples were taken per each attendee: an hrHPV test sample (HC
2
r) for primary screening test and a VCE smear for the cytological
triage test. The two spatular subsamples of the VCE smear were
collected with wooden or plastic Ayre’s spatulas and the
endocervical subsample with the special cone-shaped cervical
sampler brush of the HC 2
r test kit. After the VCE smear was
prepared from the subsamples, the tip of the cervical sampler
brush was placed into HC 2
r transport medium tube to bring it
into hrHPV test sample, and the tube was labelled with a sticker
containing the same patient information as the VCE smear. In the
case that the screenee explicitly refused from the hrHPV test, only
a VCE smear was taken.
All the samples were sent to the Helsinki screening laboratory of
Cancer Society of Finland (CSF) within 2 weeks from the sample
taking. In the laboratory smears were stained, but only smears of
the conventional arm were immediately directed to analysis. The
intervention arm smears were either screened or stored, depending
on the primary hrHPV test result: if the hrHPV test resulted
negative (ratio of the relative light units (rlu ratio) less than 1.00),
the smear was stored unscreened; if positive (rlu ratio X1.00), the
cytological analysis was carried out. In case the primary hrHPV
test sample was erroneously not taken, primary cytological
analysis was carried out instead, as in the conventional arm. The
few hrHPV test samples collected in the conventional arm were not
analysed but destroyed.
In the conventional arm, positive cytology test result (Pap class
III–V) was confirmed with colposcopy and biopsies. In the hrHPV
screening arm, in case of a single positive primary screening test,
the potential need of histological confirmation was assessed by the
cytology triage test, that is, confirmation with colposcopy and
biopsies was carried out only when cytological result was
suggestive of dysplasia or cancer (Pap class III–V); instead,
cytological normal to benign changes (Pap class I–II) were
considered a reason for intensified screening due to current
hrHPV infection and, thus, after 12 months from the initial visit a
risk group invitation within the organised programme was to
follow. Within the risk group screening, women with persistent
hrHPV infection, indicated by repeated hrHPV positivity, will be
identified and eventually referred for colposcopy (not reported
here). Colposcopies of both screening arms were conducted in
local hospitals for six municipalities, and for one municipality
(Vantaa) they were done in the practice of CSF, located in
connection with the CSF Helsinki screening laboratory. At any
stage, hrHPV test results were not blinded from the laboratory and
hospital personnel.
Ethical issues
Before launching the trial, our hrHPV screening design with
cytology triage protocol was accepted by the principal authorities
in medico-ethical issues in Finland, the National Authority for
Medicolegal Affairs and the Ethical Committee of Obstetrics and
Gynecology in Hospital District of Helsinki and Uusimaa, which
enabled running of the trial within the Finnish cervical screening
programme, that is, launching routine screening arm with primary
hrHPV testing. Also, health boards of the contacted municipalities
gave their acceptance to routine hrHPV screening with the current
design. Sample-takers of the participating municipalities received a
half-day training for the technical procedures of HC 2
r sample
taking and for informing the attending women of the hrHPV
screening and of the implication of their individual randomisation
status; the manufacturers’ representative trained for 3 days the
personnel of the responsible screening laboratory for HC 2
r
analysis.
Permission of the National Authority for Medicolegal Affairs
stated, on the basis of the Act of the Medical Use of Human Organs
and Tissues (2001), that as the randomised implementation of
hrHPV testing to the nation-wide cervical screening programme
was expected to result in a very large number of primary hrHPV
tests, collecting an informed consent from each attendant was not
required; instead, invited women had to be properly informed on
different screening modalities prior to the screening visit, and
women not willing to have an hrHPV test were to be screened with
conventional method. For this, we designed a brochure containing
essential information on cervical cancer epidemiology, role of HPV
infection in the cancer development, purpose of cervical screening,
screening visit procedures and hrHPV testing within the routine
screening, which was mailed together with the personal invitation
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sletter for the targeted women in the participating municipalities.
The individual randomisation status was not given in the
invitation letter, as we considered that it might affect the
participation rate, but it was discussed during the screening visit
to allow women to refuse from the hrHPV test.
Statistical analysis
As our aim was to measure the relative validity parameters for
routine screening, we calculated the relative sensitivity (relative
risk (RR)), specificity and positive predictive value (PPV)
estimates for both arms by intention to screen. Relative risks of
referral and histologically confirmed CIN were estimated in the
hrHPV screening arm with 95% confidence intervals (CI) using the
conventional screening arm as the reference (Miettinen &
Nurminen, 1985). Specificity was defined as the proportion of
the screening test negatives among those with no histologically
confirmed lesion (including also those without biopsy). For the
hrHPV screening arm, specificity was calculated with two
definitions for test negativity: (1) primary screening test negative
(see Figure 1 and Table 1) and (2) cytology triage negative (i.e. no
referral for colposcopy). Similarly, PPVs were calculated for the
hrHPV screening arm with two different cutoffs for test positivity:
(1) primary screening test positive and (2) cytology triage positive
(i.e. referral for colposcopy). Eventually, to clarify the significance
of the observed differences in specificity estimates between study
arms, we calculated 95% CIs for specificity with a binomial test.
RESULTS
The number of women invited to hrHPV and conventional
screening during the year 2003 was 14149 altogether (7060 and
7089, respectively). Of the invited women 9303 attended (65.8%),
4653 (65.9%) in the hrHPV screening arm and 4650 (65.6%) in the
conventional arm. The random allocation (intention to screen) was
followed completely in the conventional arm, as all 4650 women
had a cytological screening test. Instead, 408 women (8.8%) in the
hrHPV screening arm were screened primarily with cytology – for
the rest of the 4245 women, the primary hrHPV screening protocol
was followed as intended (Figure 1). The mean age in the hrHPV
arm was 45.8 years and that in the conventional arm 45.9, ranging
in both arms from 30 to 60 years. Symptoms were reported equally
often in the hrHPV and the conventional arm, in 10.2 and 10.1%,
respectively.
Of the 4245 women tested for oncogenic HPV types, 395 (9.3%)
turned out to be positive and, following the hrHPV screening
protocol, cytology triage test was carried out for them. Based on
the cytological test result, 60 hrHPV-positive women were
eventually referred for colposcopy. Additional five referrals were
made in the hrHPV arm among women screened primarily with
cytology. In the conventional arm, a total of 43 women were
referred (Table 1).
Compared with the conventional arm, clearly more colposcopy
referrals were made in the hrHPV screening arm (RR 1.51, CI 95%
1.03–2.22). As a result of performed colposcopies, a total of 52
2407 Not participated
3850 hrHPV test negative
335 Pap class I−II,
 no reason for colposcopy
27 No CIN detected
33 CIN lesions detected
60 Pap class (II)III−V,
     referral for colposcopy
395 hrHPV test positive,
 Pap smear screened
4245 Screened primarily
with hrHPV test
403 Pap class I−II,
 no reason for colposcopy
5 No CIN detected
5 Pap class (II)III−V,
   referral for colposcopy
408 Screened primarily
 with Pap test
4653 Participated (65.9%)
7060 Allocated to
  hrHPV screening arm
2439 Not participated
4607 Pap class I−II,
    no reason for colposcopy
24 No CIN detected
19 CIN lesions detected
43 Pap class (II)III−V,
     referral for colposcopy
4650 Screened primarily
with Pap test
4650 Participated (65.6%)
7089 Allocated to
   conventional arm
14 149 Women identified, randomised
 and invited to screening
Figure 1 Randomised screening flow: participation, contamination, test positivity and confirmatory test results in the two arms.
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shistologically confirmed precancerous lesions were detected within
the study population: 33 in the hrHPV screening arm and 19 in the
conventional arm. In the hrHPV screening arm, 17 of the lesions
were low grade (CIN1), 10 moderate (CIN2) and six severe
(CIN3þ); in the conventional arm, they were eight, five and six,
respectively. Relative risk point estimate for any CIN in the hrHPV
screening arm was 1.74 (Table 2), which was not statistically
significant, however. All lesions in the hrHPV arm were found
among the hrHPV-positive women (see Figure 1).
In the hrHPV arm, specificity for the sole primary screening test
was 92.1% for any lesion (CIN1þ), 91.7% for moderate to severe
lesions (CIN2þ) and 91.5% for severe lesions (CIN3þ). For the
hrHPV screening with cytology triage, specificity estimates were
99.3, 98.9 and 98.7%, and for the conventional arm 99.6, 99.3 and
99.2%, respectively (Table 3).
For the sole primary screening test positivity, PPVs in the
hrHPV screening arm were low, from 1.5 to 8.0% depending on the
histological threshold. On the contrary, PPVs obtained with
cytology triage (from 9.2 to 50.8%) were much more like those
in the conventional arm (from 14.0 to 44.2%) (Table 4).
DISCUSSION
In the current paper, we have reported the first-year results of
primary hrHPV screening and of cytology triage protocol,
incorporated in an existing cervical screening programme by
randomised design. As a result, we observed a significant increase
of 51% in the referrals of the hrHPV screening arm compared with
the conventional arm. The detection rate at the level of mild and
moderate dysplasia was two times higher in the hrHPV screening
arm than in the conventional arm, but the same at the level of
severe dysplasia. However, differences in detection rates were
subject to considerable random variation and even more so
with more stringent cutoff levels. Observed increase in cross-
sectional relative sensitivity in hrHPV arm would have been
acquired at the cost of substantial loss in specificity; however, with
cytology triage the specificity was improved to the level of
conventional cytology.
As the current results derive from a randomised population-
based study analysed by intention to screen, most of the biases are
avoided. Randomisation seems to be adequately performed, as no
marked differences were seen between arms when comparing
attendance rates, mean ages and reported symptoms. Although the
Table 1 Primary screening test results, colposcopy referrals and distribution of Pap class led into referral
hrHPV arm Conventional arm
Primary hrHPV test Primary Pap test Primary Pap test
Screening test result n¼4245 % n¼408 % n¼4650 %
Primary test negative 3850 90.7 403 98.8 4607 99.1
Primary test positive 395 9.3 5 1.2 43 0.9
Colposcopy referral
a 60 1.4 5 1.2 43 0.9
Pap class II 3 0.1 0 0.0 3 0.1
Pap class III 55 1.3 5 1.2 36 0.8
Pap class IV 2 0.0 0 0 4 0.1
Pap class V 0 0.0 0 0 0 0.0
aIn the hrHPV arm based on the result of cytological analysis carried out for the hrHPV positive (see study design for the protocol).
Table 2 Relative risk of colposcopy referral and histological findings in the hrHPV arm compared with the conventional arm
hrHPV arm Conventional arm
Colposcopy n¼4653 % n¼4650 % RR 95% CI
Referral 65 1.40 43 0.92 1.51 1.03–2.22
Any CIN 33 0.71 19 0.41 1.74 0.99–3.05
CIN1 17 0.37 8 0.17 2.12 0.92–4.92
CIN2 10 0.21 5 0.11 2.00 0.68–5.84
CIN3+ 6 0.13 6 0.13 1.00 0.32–3.10
RR¼relative risk; CI¼confidence interval.
Table 3 Specificity of the sole hrHPV test and hrHPV screening with
cytology triage in comparison with conventional screening calculated with
three histological cutoffs
Cutoff
No histological
confirmation or
negative at cutoff
(n)
Screening
test negative
(n)
Specificity
(%)
95% CI
(%)
hrHPV arm, sole hrHPV test (n¼4653)
CIN1+ 4620 4253 92.1 91.2–92.8
a
CIN2+ 4637 4253 91.7 90.9–92.5
a
CIN3+ 4647 4253 91.5 90.7–92.3
a
hrHPV arm, cytology triage (n¼4653)
CIN1+ 4620 4588 99.3 99.0–99.5
CIN2+ 4637 4588 98.9 98.6–99.2
CIN3+ 4647 4588 98.7 98.4–99.0
b
Conventional arm (n¼4650)
CIN1+ 4626 4607 99.6 99.4–99.8
CIN2+ 4639 4607 99.3 99.0–99.5
CIN3+ 4644 4607 99.2 98.9–99.4
hrHPV¼high-risk human papillomavirus; CI¼confidence interval.
aIn comparison to
the specificity of the conventional arm with the same histological cutoff, Po0.0001.
bIn comparison to the specificity of the conventional arm with the same histological
cutoff, Po0.05.
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sattendance rate in the participating municipalities (65.8%) was
lower than the mean in Finland (ca. 70%), it was about the level it
had been in these municipalities during the previous years.
Contamination rate in the intervention arm remained at moderate
level (8.8%) and did not interfere with making the interpretations.
Lack of blinding is the most potential cause of bias, as it might
have affected the observed increase in referral and detection
rates: the increase may result either from higher sensitivity of
the hrHPV test or from overdiagnosis, that is, indolent lesions
without potential of progression are detected as cytological,
colposcopical and/or histological criteria are changed due to
the knowledge on hrHPV status. However, as the study is run
within routine programme, blinding was considered unnecessary.
The reason of the observed increase will be verified in the
subsequent follow-up of the women, together with the outcome
evaluation.
Prior to our study, randomised trials on hrHPV testing in
primary cervical screening have been conducted in Costa Rica
(Guanacaste), USA (ASCUS-LSIL Triage Study, ALTS), The
Netherlands (POBASCAM trial) and India. In the Guanacaste trial,
sensitivity and specificity of the HC 2
r testing were compared to
Pap testing using ASC-US cut point for colposcopy (Schiffman
et al, 2000); however, the women tested for hrHPVs had multiple
tests (a pelvic examination, conventional cytological test and LBC
test, cervigrams) performed, which makes evaluating the outcome
effectiveness of these tests impossible (The working group of
IARC, 2005). Like in our study, in the ALTS and POBASCAM trial
women were randomised to intervention and control groups, but
in these trials hrHPV test (by HC 2
r in ALTS and by GP5þ/6þ
PCR immunoassay in POBASCAM) was used as a confirmatory
test for cytological test, which is just the opposite to our study
(Schiffman and Solomon, 2003; Bulkmans et al, 2004). The Indian
trial, being most comparable to our study, resulted in specificity of
HC 2
r test in detecting CIN2þ lesions ranging from 91.7 to
94.6%, and PPV from 9.1 to 16.7% – for the same cutoff in the
current study, specificity estimate was 91.7% and PPV 4.0%
(Sankaranarayanan et al, 2004). However, virtually all women in
the Indian trial had histological confirmation, which did not
happen in our study, as our ultimate aim is to evaluate the
program effectiveness at the level of interval cancers; this kind of
evaluation will not be possible in India, as the precancerous lesions
of both test negative and test positive women were detected and
treated.
Our results confirm the common finding that testing for hrHPVs
is more sensitive but less specific than conventional cytological
testing. Based on literature and our own pilot study results, this
was what we had expected – being convinced that primary
screening with sole hrHPV test would result in a substantial
increase in the number of colposcopies (and moreover, increase in
total costs and a possible increase in the reported adverse effects)
in a country like Finland, where only clearly suspicious cytological
findings (Pap class III–V) are traditionally considered a reason for
colposcopy referral, we included a more specific confirmatory test,
cytology triage, to our screening design (Nieminen et al, 2004). In
addition, to not to increase the number of screening visits and
dropouts in the hrHPV screening arm due to the two-staged
confirmation, we decided that the sample for this cytology test was
to be taken at the first visit together with hrHPV test sample. To
reassure that the hrHPV test sample and endocervical subsample
of the smear were taken exactly from the same location, only one
brush sample was taken and used first for the smear and second
for the hrHPV test.
Based on the first-year experience, cytology triage succeeded well
in reducing the number of colposcopy referrals compared to the sole
hrHPV test, which, from our point of view, seems justified as the
primary screening method only if cytologists are not available in
sufficient numbers: with moderate resources for cytological analysis,
savings in the colposcopical resources may be earned. However, the
hrHPV test itself is relatively expensive for screening purposes,
especially when compared to conventional Pap smear; we have
covered the excess costs of the hrHPV screening for the
municipalities to keep the study ongoing. As lack of financial,
infrastructural and manpower resources has prohibited the cyto-
logical screening programmes to start in low-resource countries, it is
presumable that any form of hrHPV screening is too sophisticated
and expensive to be feasible and effective in these countries, unless
the hrHPV testing is made significantly cheaper and less dependent
on hi-tech systems (Sankaranarayanan et al,2 0 0 4 ) .
Interpretations on screening technologies have often been made
on the basis of intermediate indicators instead of outcome
(interval cancer rate) evaluation, and issues like overdiagnosis
and other possible adverse effects of screening have not been
widely discussed. Yet, sensitivity and effectiveness of the screening
tests for cervical cancer can be reliably estimated only by means of
interval cancer incidence for invasive disease. Without clear
scientific evidence of better effectiveness of the screening
programme with a new screening test, it is rational not to change
a well-functioning existing programme: in ultimate outcome
evaluation, it may turn out that the new screening modality is
much more expensive to use, causes more adverse effects or
anxiety and the results in terms of cancer incidence are hardly any
better than with the old test. Interventions may produce different
outcomes in effectiveness and efficiency in different countries,
depending on their infrastructure and pre-existing screening
programmes. Thus, we will continue the intake and the follow-
up, and expand the population covered by hrHPV screening, as the
results shown in this paper justify the further evaluation of this
specific screening modality.
In conclusion, compared with conventional cytology, primary
screening with hrHPV test results in increased cross-sectional
relative sensitivity at the level of all positive lesions at the cost of
substantial loss in specificity. With cytology triage the specificity
improves to the level of conventional cytology.
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Table 4 Positive predictive value of the sole hrHPV test and hrHPV
screening with cytology triage in comparison with conventional screening
calculated with three histological cutoffs
Cutoff
Screening test
positive (n)
Positive histology
at cutoff (n) PPV (%)
hrHPV arm, sole hrHPV test (n¼4653)
CIN1+ 400 33 8.0
a
CIN2+ 400 16 4.0
a
CIN3+ 400 6 1.5
a
hrHPV arm, cytology triage (n¼4653)
CIN1+ 65 33 50.8
CIN2+ 65 16 24.6
CIN3+ 65 6 9.2
Conventional arm (n¼4650)
CIN1+ 43 19 44.2
CIN2+ 43 11 25.6
CIN3+ 43 6 14.0
hrHPV¼high-risk human papillomavirus; PPV¼positive predictive value.
aIn
comparison to the specificity of the conventional arm with the same histological
cutoff, Po0.0001.
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